Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study
H Rajasekeran, HN Reich… - American Journal …, 2018 - journals.physiology.org
Focal segmental glomerulosclerosis (FSGS) is an important cause of nondiabetic chronic
kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition (SGLT2i) therapy …
kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition (SGLT2i) therapy …
[HTML][HTML] Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study
H Rajasekeran, HN Reich… - American Journal …, 2018 - journals.physiology.org
Focal segmental glomerulosclerosis (FSGS) is an important cause of nondiabetic chronic
kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition (SGLT2i) therapy …
kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition (SGLT2i) therapy …
[HTML][HTML] Translational Physiology: Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study
H Rajasekeran, HN Reich… - American Journal of …, 2018 - ncbi.nlm.nih.gov
Focal segmental glomerulosclerosis (FSGS) is an important cause of nondiabetic chronic
kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition (SGLT2i) therapy …
kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition (SGLT2i) therapy …
Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.
H Rajasekeran, HN Reich… - American Journal of …, 2017 - europepmc.org
Focal segmental glomerulosclerosis (FSGS) is an important cause of nondiabetic chronic
kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition (SGLT2i) therapy …
kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition (SGLT2i) therapy …
[PDF][PDF] Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study
H Rajasekeran, HN Reich… - Am J Physiol Renal …, 2018 - scholar.archive.org
Focal segmental glomerulosclerosis (FSGS) is characterized by proteinuria and renal
function decline, leading to chronic kidney disease (CKD) and end-stage renal disease …
function decline, leading to chronic kidney disease (CKD) and end-stage renal disease …
Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study
H Rajasekeran, HN Reich… - American journal …, 2018 - pubmed.ncbi.nlm.nih.gov
Focal segmental glomerulosclerosis (FSGS) is an important cause of nondiabetic chronic
kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition (SGLT2i) therapy …
kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition (SGLT2i) therapy …
Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study
H Rajasekeran, HN Reich, MA Hladunewich… - American Journal of …, 2018 - cir.nii.ac.jp
抄録< jats: p> Focal segmental glomerulosclerosis (FSGS) is an important cause of
nondiabetic chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition …
nondiabetic chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition …
Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.
H Rajasekeran, HN Reich… - American Journal of …, 2017 - europepmc.org
Focal segmental glomerulosclerosis (FSGS) is an important cause of nondiabetic chronic
kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition (SGLT2i) therapy …
kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition (SGLT2i) therapy …